Discussion  by unknown
BAC behave much differently than other NSCLCs. Obser-
vation of resectable lung cancer would require a new treat-
ment paradigm based on a tumor’s specific predicted be-
havior. Retrospective reviews may not be able to validate
this idea, and at the present time randomized trials do not
exist.
Conventional chemotherapy has had poor results with
BAC, but newer drugs such as epidermal growth factor
receptor-tyrosine kinase inhibitors, “Iressa,” and vaccine
therapies have shown some initial promise.17 Studies eval-
uating the role of these drugs specifically in BAC are
ongoing. Perhaps these drugs will improve survival in both
early and advanced stages of BAC. Unanswered questions
and different opinions reflect the complexities and hetero-
geneity of this tumor subtype.
Confusion would result if modifications were made to
the lung cancer staging system too frequently. This would
translate into difficulty in patient care, clinical trial devel-
opment and interpretation, and comparisons of data among
institutions. Thus, even though we believe that the current
staging system is inadequate for multifocal N0 BAC, we
continue to use it. However, we support previous reports
that indicate a need for ongoing evaluation with eventual
modifications to the staging system based on the collection
of more data. We hope that a greater understanding of
individual tumor biology will add to the clarity and accu-
racy of new staging systems that may take into account
tumor type.
On the basis of our experience, we continue to evaluate
multifocal disease when BAC is present with an eye toward
resection. Although many of these patients will be clinically
staged IIIB or IV, we recommend operation when complete
resection can be safely achieved. Even in cases of repeat
resections, long-term survival can be achieved.
We acknowledge Ronald Hayes, PA-C, and Shirley Cable for
their great assistance in data collection and preparation of this
article.
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Discussion
Dr Richard Whyte (Stanford, Calif). In this article, the authors
present the outcomes of 14 patients with multifocal BAC of the
lung. They suggest that a conventional staging system would
assign these patients to either stage IIIb or IV depending on
whether the lesions are in the same lobe or different lobes, and that
such patients would have an anticipated survival of less than 10%.
The observed survival was greater than 60%, and this clearly
indicates one of the shortcomings of the conventional staging
system. It is very helpful for us to know what happens to these
patients in the long run.
Dr Roberts, I have 3 questions for you. First, your patients with
multifocal disease seem to represent approximately 20% of the
patients with BAC whom you have seen. What happened with the
other 80%? Were they followed in the long run for many years? If
so, would you expect your 20% to actually be a significantly higher
percentage of all the patients with BAC presenting with multifocal
disease?
Dr Roberts. One deficiency of our study is that we did not
review all of the pathology slides. Perhaps some of the other
patients whom we have treated for multifocal disease in fact had
BAC, and it is true that what appears to be unifocal disease may
some day be multifocal disease or recurrence. We did not review
in detail all of our other patients with BAC, but the overall survival
of those patients does seem to be about what you would expect
with stage I NSCLC.
Dr Whyte. My second question relates to the nomenclature of
BAC. In our weekly tumor board meetings, we frequently hear
about adenocarcinoma with bronchoalveolar features versus BAC.
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I am wondering if you could tell us the current status of the
nomenclature there and how these 2 entities differ.
Dr Roberts. That certainly seems to be one of the areas central
to this issue, and there remains some controversy. There are
various groups that have looked at BAC and continue to use
various designations and definitions. In our group, we define BAC
as tumors with isolated bronchoalveolar features. The 3 patients in
undetermined tumor stages are in fact patients who had adenocar-
cinoma with some BAC features in 1 of their lesions. I am not sure,
and I do not know if anybody is, whether those tumors that are
adenocarcinoma with BAC features and then have a second foci of
BAC represent a true metastasis (it is certainly possible that as the
tumor metastasizes, it undergoes some metamorphosis) or in fact
whether those are distinct second primary tumors.
Dr Whyte. My last question refers to the variability in opera-
tions you performed. There were a substantial number of lobecto-
mies and wedge resections and a couple of segmentectomies. Did
you see any difference in the survival depending on the operation
that was performed? And what operation would you perform now
in someone who presents with BAC? Would you perform a wedge
resection or a lobectomy as we have typically been taught?
Dr Roberts. That also is a great debate. Unfortunately, our
numbers are too small to perform much analysis in terms of the
type of operations. I believe that the clonality issue is important
when considering that. People who have claimed a multiclonal
origin have recommended limited resection, that is, wedge resec-
tion, because people are likely to come up with a recurrence based
on that fact. Presently, if we identify a BAC as a single lesion, we
will typically treat it as other NSCLCs and perform an anatomic
resection. However, in the case of multifocal disease, when the
second lesion is easily removed with either a segmentectomy or
wedge resection, then we would perform those operations.
Dr Douglas E. Wood (Seattle, Wash). I have a couple of
questions and a comment on the pathologic definitions you were
just talking about.
BAC is a noninvasive tumor, and when the tumor has gone
through the basement membrane, it is an adenocarcinoma. One of
the difficulties is in always detecting the tumor invasion, but I
guess I would ask that when a tumor shows adenocarcinoma
invasive features, should we throw out all of this discussion about
BAC and treat it as an adenocarcinoma?
Dr Roberts. I believe that we should if there is true invasion
and if we use the definition (I should say our pathologists use the
definition) of BAC as the absence of any stromal, pleural, or
vascular invasion.
Dr Wood. In that situation, nodal disease is not possible with
BAC, which is why BAC behaves differently and why we have the
benefit of your experience in being able to resect multifocal
disease and the extent of resection not needing to be what we
consider for a standard invasive lung cancer. Your experience also
shows that many times these patients are coming back for repeated
procedures, and that certainly warrants at least a consideration for
conservative limited resections, at least when we know that some-
body has pure BAC.
I disagree a little bit with excluding the 32 patients who had
incomplete resections. There were apparently 46 patients with
multifocal disease, 14 of whom had complete resections, and there
is great survival in those patients. But is that a fair description of
the true oncologic survival in multifocal disease? If we then again
include the denominator of multifocal disease (and I am going to
make the presumption that all of those 32 died), the true survival
would be approximately 20% rather than 64%. Am I wrong in the
logic of including those patients? What do you think about nar-
rowing the denominator as much as you have, which has resulted
in the outstanding long-term survival?
Dr Roberts. The slide was probably misleading, and your logic
is probably correct, but my representation of the patients may not
be. The approximately 30 patients did not undergo incomplete
resections; there were only actually a couple who underwent
incomplete resections. Most of those patients underwent biopsies
for diagnosis. Those were included in our surgical pathology
database review, but there were really only a couple of people who
underwent incomplete resections. I agree with you that if the
number 32 in fact represented 32 people whom we treated but
could not cure, that would certainly skew it, but that is not the case.
Dr William Brenner (Hackensack, NJ). Dr Roberts, your
presentation reminded me that about a decade ago during grand
rounds at University of California-Los Angeles, a senior patholo-
gist showed that this disease (which seemed to be increasing in
young women in the Los Angeles area) was histopathologically
identical to a viral disease of sheep in South Africa. Your anecdote
of a husband and wife both having this same carcinoma is certainly
a very compelling indication that it may be have a totally different
cause than most lung cancers.
Dr Thomas Rice (Cleveland, Ohio). Thank you very much for
the stimulating article and the rather bold statement. I think the
definition of BAC is key to the problem. You say that 5 of the 14
patients had mixed cell types, and I believe that 1 patient probably
had metastatic pancreatic carcinoma. The best case of BAC in
medical school was metastatic biliary cancer, so that leaves 6 of
your 14 or 8 patients possibly with BAC. Did you perform any
studies to look at flow cytometry or polymerase chain reaction to
determine if these are similar clones? Are they truly multifocal
BAC?
It is also key, as you presented in case 14, whether these are
metachronous or synchronous carcinomas. I think many of your
synchronous presentations that have done so well may be synchro-
nous primary cancers.
Dr Roberts. Again, these are all difficult issues, and we did not
make any attempt to perform flow cytometry or determine clonal-
ity. All patients had at least 1 foci of BAC. As I said, there were
a couple of patients who had BAC features in their other tumor
adenocarcinoma features. I think it is important to consider all of
those patients together because when you are considering multi-
focal resection, the behavior of each of the tumors added or
multiplied together will determine their outcome. Going back to
the coin analogy, if 1 of the coins you are flipping is double-
headed, and perhaps that is the case we have with BAC (that the
very early BACs are more curable by resection), then a BAC
combined with another tumor of a different cell type may give a
good prognosis.
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